This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.



Michael Houghton

University of Alberta

Michael Houghton is a Professor in the department of medical microbiology & immunology at the University off Alberta and is also Director of the Li Ka Shing Applied Virology Institute at this university.

Together with Qui-Lim Choo and George Kuo at the Chiron Corporation in the USA and in collaboration with Dan Bradley of the CDC, he identified HCV in 1989 after an intensive 7 year search and then developed a series of HCV diagnostic tests now used around the world. Again working with Drs Choo & Kuo, he published the first demonstration of prophylactic efficacy of a HCV vaccine candidate in 1994, work that he has continued since joining the University of Alberta in 2010.

Currently, he and Alberta colleagues are manufacturing an improved HCV vaccine candidate in preparation for clinical testing in the near future.